Purpose Breast fibroglandular tissue (FGT), as visualized on a mammogram (mammographic density, MD), is one of the strongest known risk factors for breast cancer. FGT is also visible on breast MRI, and increased background parenchymal enhancement (BPE) in the FGT has been identified as potentially a major breast cancer risk factor. The aim of this exploratory study was to examine the biologic basis of BPE. Methods We examined the unaffected contra-lateral breast of 80 breast cancer patients undergoing a prophylactic mastectomy before any treatment other than surgery of their breast cancer. BPE was classified on the BI-RADS scale (minimal/ mild/moderate/marked). Slides were stained for microvessel density (MVD), CD34 (another measure of endothelial density), glandular tissue within the FGT and VEGF. Spearman correlations were used to evaluate the associations between BPE and these pathologic variables. Results In pre-menopausal patients, BPE was highly correlated with MVD, CD34 and glandular concentration within the FGT, and the pathologic variables were themselves highly correlated. The expression of VEGF was effectively confined to terminal duct lobular unit (TDLU) epithelium. The same relationships of the four pathologic variables with BPE were seen in post-menopausal patients, but the relationships were much weaker and not statistically significant. Conclusion The strong correlation of BPE and MVD together with the high correlation of MVD with glandular concentration seen in pre-menopausal patients indicates that increased breast cancer risk associated with BPE in pre-menopausal women is likely to result from its association with increased concentration of glandular tissue in the FGT. The effective confinement of VEGF expression to the TDLUs shows that the signal for MVD growth arises directly from the glandular tissue. Further studies are needed to understand the basis of BPE in post-menopausal women. 
Introduction
Breast magnetic resonance imaging (MRI) is used for screening and clinical management of breast cancer patients. Normal breast fibroglandular tissue (FGT), as visualized on a mammogram (mammographic density, MD), is one of the strongest known risk factors for breast cancer [1] . FGT is also visible on breast MRI (MRI-FGT) and signal intensity in the FGT increases to varying extents after administration of MRI-contrast medium [2] ; this increase is referred to as background parenchymal enhancement (BPE) and is classified on the American College of Radiology's (ACR) Breast Imaging Reporting and Data System (BI-RADS) four-point BPE scale (minimal/mild/moderate/marked) [2] . In a study of 39 breast cancer cases and 78 age-matched controls, King et al. [3] found that there was an increasing risk of breast cancer with increasing levels of BPE with the relative risk (RR) increasing from 1.0 with a minimal/ mild BPE, to 4 or greater with a moderate/marked BPE. The increased risks were found in pre-menopausal and postmenopausal women. Large relative risks were also found in age-matched case-control studies reported by Dontchos et al. [4] and by Telegrafo et al. [5] , and in the study of Wu et al. [6] although they did not report their findings using the BI-RADS BPE coding scheme. In their age-matched casecontrol study, Grimm et al. [7] found a smaller effect-RR of 2.5 for mild/moderate/marked compared to minimal. Telegrafo et al. [5] reported that similar risks were seen in pre-menopausal and post-menopausal women; the reports on the other studies did not describe their results separately for pre-menopausal or post-menopausal women. Although Bennani-Baiti et al. [8] reported that they found no effect of BPE on risk of breast cancer in their case-control study, their cases were much older than their controls and no details of how they accounted for this were given in the paper. BPE is distinct from the amount of FGT [9] and the studies that have reported on this have found that the risk from high BPE was independent of the risk associated with FGT [3, 4, 6, 7] .
BPE is highly responsive to changes in the hormonal environment of the breast. It decreases with menopause [10, 11] and with tamoxifen [12] or aromatase inhibitor treatments [13, 14] , all of which decrease breast cancer risk. It increases with menopausal hormone therapy [15] [16] [17] , but it is not clear whether the effect is greater with estrogenprogestin therapy, which increases risk of breast cancer more than estrogen-alone therapy [18] . These changes in BPE are more pronounced than the hormonally-mediated changes seen in MRI-FGT [12, 13] .
The BI-RADS classification of BPE is made with reference to "glandular tissue": minimal is defined as "less than 25% of glandular tissue demonstrating enhancement", mild as "25-50% of glandular tissue demonstrating enhancement", moderate as "50-75% of glandular tissue demonstrating enhancement", and marked as "more than 75% of glandular tissue demonstrating enhancement" [2] . In practice, "glandular tissue" is interpreted as "fibroglandular tissue" [2, 19] . It is assumed that the enhancement must come from microvessels in the FGT [20] and that these must be generated by the glandular tissue within the FGT [2, 8] , but there is no direct evidence of this.
We report here, the results of a study we conducted of the histopathologic correlates of BPE to obtain direct evidence related to these assumed effects. We studied the contra-lateral cancer-free breast of women with breast cancer who underwent a bi-lateral contrast-enhanced breast MRI and prophylactic mastectomy prior to any treatment other than surgery for their breast cancer. We hypothesized that higher levels of BPE would be associated with higher levels of microvessel density (MVD) and with the concentration of glandular tissue in the FGT. As a secondary aim, we also studied the concentration of markers of inflammation as inflammation is thought to play a role in breast cancer etiology and may be related to the extent of BPE [21, 22] , and estrogen receptor α (ERα) and progesterone receptor (PR), and a marker of cancer stem cells.
Materials and methods
In this exploratory study, we identified 80 uni-lateral breast cancer patients, who had a prophylactic contra-lateral mastectomy before they had received any treatment other than surgery. We studied a variety of aspects of their contra-lateral breast tissue and related these findings to their level of BPE.
Patients
The Memorial Sloan Kettering Cancer Center (MSK) Institutional Review Board granted permission to conduct this Health Insurance Portability and Accountability Act compliant retrospective study. A waiver of patient consent was granted to conduct a retrospective review of the radiology and pathology records of breast cancer patients who (1) had consented to the MSK global biospecimen ascertainment protocol, and (2) had a contrast-enhanced bi-lateral breast MRI before breast surgery or any adjuvant breast cancer treatment. By searching the medical records over the period 2008 through 2014, we identified the subset of women who had a uni-lateral breast cancer and a subsequent prophylactic mastectomy of their contra-lateral breast that showed no evidence of breast cancer. The waiver of consent covered our immunohistochemical study of the paraffin-embedded tissues obtained from the non-cancer breast of such patients and the correlation of the immunohistochemistry with the BPE findings in the non-cancer breasts.
Patients were excluded if, at the time of MRI or breast surgery, they had breast implants; were taking oral contraceptives, post-menopausal hormone therapy, or other hormonal medications (e.g., tamoxifen); or were pregnant or breast feeding within 6 months; or were < 21 or ≥ 70 years of age. Women with a history of any cancer (apart from nonmelanoma skin cancer) were also excluded as prior systemic treatments may confound any measurements we made.
We reviewed hospital charts and reports to obtain information on prior surgeries, biopsies, diagnoses of benign breast disease, and hormonal medication use. In this exploratory study, we sought to identify 80 patients meeting the initial eligibility criteria: 20 patients from each of the following four groups: pre-menopausal with minimal/mild BPE; premenopausal with moderate/marked BPE; post-menopausal with minimal/mild BPE; and post-menopausal with moderate/marked BPE.
MRI readings
All MRI readings were first carried out by a single radiologist (JSS). MRI-FGT was assessed using a T1-weighted non-fat-suppressed series and categorized using the fourpoint BI-RADS FGT scale (predominantly fatty/scattered/ heterogeneously dense/dense). We excluded patients with fatty MRI-FGT breasts to help ensure that there was sufficient FGT for the pathology analyses. BPE was assessed using a T1-weighted fat-suppressed sequence from the precontrast, the first post-contrast series and the subtraction image (subtraction of the pre-contrast image from the first post-contrast image). BPE was categorized using the fourpoint BI-RADS BPE scale.
The BPE readings were also carried out by a second radiologist (DMK) completely independently of the initial BPE readings using the same methods on the same MRIs. The main results in the paper are given using the readings of JSS, and comparisons are made between the results using the readings of JSS to the readings obtained by DMK, which are given in Supplementary Tables 1 and 2 .
Histology
The following markers were selected for study: MVD, CD34 [23] and VEGF [24] to quantify the degree of vascularization and ongoing angiogenesis; the glandular concentration in the FGT; COX2 [25] and TGFβ [26] as markers of inflammation and macrophage-adipocyte complexes (crown-like structures) for their possible association with release of inflammatory cytokines [27] . We also studied estrogen receptor α (ERα) and progesterone receptor (PR); and the presence of CD44 cells in the absence of CD24 cells as a marker of cancer stem cells [28] .
Immunohistochemical (IHC) studies were performed using the formalin-fixed paraffin-embedded tissue blocks that appeared to contain the most FGT, one to two tissue blocks from each patient were chosen with no knowledge of the breast BPE or any clinical factors. All quantifications were made restricting attention to the FGT. Multiple sequential sections from the chosen blocks were cut at 5 µm, and followed the standard MSK Pathology Department protocol for IHC processing. IHC stains for were performed for CD24, CD34, CD44, CD31/PECAM-1, COX2, ERα, PR, TGFβ, and VEGF, with appropriate positive and negative controls for each stain. Sources and dilutions of the primary antibodies were: CD24-polyclonal CD24 antibody, Biorbyt, at 1:50 dilution; CD34-clone 4H11, LSBio, ready to use (RTU); CD44-clone 156-3C11, Neomarkers, at 1:200 dilution; CD31/PECAM-1-clone TLD-3A12, Novus, RTU; COX2-clone COX229, LSBio, RTU; ERα-clone 6F11, Leica, RTU; PR-clone 16, Leica, RTU; TGFβ-clone TB21, Abcam, at 1:50 dilution; and VEGF-clone JH, Millipore Sigma, RTU.
MVD was recorded as the number of CD31/PECAM-1-staining microvessels per 200 × HPF in the stroma in five 200 × HPFs containing the highest number of TDLUs. Other IHC stains were assessed in 10 microscopic fields containing the highest number of TDLUs, at multiple magnifications (2×, 4×, 10× and 20× HPFs). CD34 was recorded semi-quantitatively from weak to strong (+, ++, +++) in membranous staining of endothelial cells ( Supplementary  Fig. 1a, Fig. 1b) . We found that VEGF staining was almost completely confined to TDLU epithelium and was recorded semi-quantitatively from weak to strong (+, ++, +++) in membranous staining of TDLU epithelial cells (Fig. 1, Supplementary Fig. 2a) .
The glandular concentration within the FGT, i.e., glandular tissue as a proportion of the FGT, was estimated on the H&E slides by visualizing 15 microscopic fields containing the most FGT at multiple magnifications (2×, 4× and 10× HPFs), and was recorded as low, medium or high (Fig. 2a, b) .
The other IHC stains were recorded as follows: ERα and PR-% nuclear staining of TDLU epithelial cells; CD24, CD44, COX2, TGFβ-positive (+) and negative (−) membranous staining of TDLU epithelial cells.
All cases were independently reviewed and scored by a single pathologist (ADC), who was blinded to the patient's age, weight, menopausal status, clinical diagnosis, and the radiologic characteristics of the breast, including the reading of FGT and BPE.
Statistical analysis
We analyzed these data using the statistical package program Stata 14 (Stata Corporation, College Station, TX, USA). Non-parametric Spearman correlations were used to calculate the statistical significance of the relationship between the pathologic factors and BPE, and to investigate the interrelationships of the various factors studied. All statistical significance levels (p values) quoted are two-sided.
Results
We identified 80 patients who had undergone prophylactic mastectomy of the non-cancer unaffected breast and who met the other inclusion criteria for the study. The distribution of the 80 patients by menopausal status and BPE category was not as precise as we had intended because we were unable to identify 20 post-menopausal patients with moderate/ marked BPE ( Table 1) .
The relationships between BPE (as read by JSS) and MVD, CD34 and glandular concentration in pre-menopausal patients are shown in Table 2 . All three factors were much higher in women with moderate/marked BPE, and the results were all highly statistically significant. VEGF expression was also strongly associated with BPE to approximately the same extent as the other three factors ( Table 2 ). All four pathologic factors were highly correlated with each other ( Table 2 ). The close relationship of VEGF with TDLU cells is illustrated in Fig. 1 , and low and high glandular concentration is illustrated in Fig. 2a, b . The relationships of the pathologic variables with BPE were slightly strengthened when the analyses were restricted to Whites.
BPE is known to vary during the menstrual cycle, with the lowest level being found in week 2 and the highest in weeks 3 and 4 [2, 29] ; the BPE level in week 1 is close to the level in week 2. We identified the week of the menstrual cycle when the MRI examinations was carried out for 41 of The same relationships of the four pathologic factors with BPE were seen in post-menopausal patients, but the relationships were much weaker and not statistically significant ( Table 3 ). The pathologic factors were again highly correlated with each other (Table 3 ).
Further analysis of the relationships between each of the four pathologic factors and BPE both in pre-menopausal women and in post-menopausal women showed that the relationships could be satisfactorily fit by linear regression models with the increasing BPE levels taking values 1, 2, 3, and 4, and the categorized pathologic variables taking values 1, 2, and 3. These analyses showed that the slope of the regression lines for the post-menopausal women were much lower than the slopes found for the pre-menopausal women: MVD (80% lower, p = 0.006), CD34 (65% lower, p = 0.005), glandular density (49% lower, p = 0.074), and VEGF (66% lower, p = 0.011). The estimated slopes (standard errors) of the post-menopausal patients were 0.320 (0.418), 0.194 (0.098), 0.291 (0.142), and No relationships were seen between BPE and CD44+/ CD24−, TGFβ, ERα, or PR in pre-menopausal or in postmenopausal patients (Tables 4, 5 ). COX2 expression was seen in all TDLUs. Crown-like structures were rarely seen.
The relationships of BPE as read by DMK to the pathologic factors were very similar to the results found for BPE as read by JSS (Supplementary Tables 2, 3 ).
Discussion
We found strong correlations of BPE with MVD, CD34, glandular concentration, and VEGF in pre-menopausal patients. As expected the two measures of endothelial density, i.e., MVD and CD34, were highly correlated. MVD and CD34 were also highly correlated with glandular concentration. Independent assessment of BPE by a second radiologist provided further support to these findings, and further analysis controlling for menstrual cycle phase showed that these correlations were not affected by cycle phase at MRI. These results are strongly supportive of the common assumption that BPE is a measure of microvessels in the FGT [20] and that microvessels are 
closely associated with the glandular tissue within the FGT [2, 8] . The biological basis of the high correlation of glandular concentration with MVD would appear to be that VEGF expression is essentially confined to TDLU cells, which comprise the glandular tissue, and VEGF is a potent mitogen for micro-and macro-vascular endothelial cells and is associated with increased vascular permeability [30] [31] [32] [33] [34] . A high correlation between VEGF expression and microvessel density was previously noted in breast cancer samples by Toi and colleagues [35] , who reported "frequent appearance of peri-ductal proliferations of microvessels around VEGF positive tumor components". These results suggest that a significant part of the risk of breast cancer associated with increased BPE in premenopausal women is due to an increased concentration of glandular tissue in the FGT. Increased FGT is likely to increase breast cancer risk due to the association of increased FGT with increased glandular tissue. This was shown in the analysis of Boyd and his colleagues [36] of the extensive data on normal breast gathered by Longacre and Bartow [37] ; in further analysis of these data, we found this to hold in both pre-menopausal and post-menopausal women. If our findings are confirmed, it will demonstrate that BPE effectively distinguishes the glandular tissue from the fibrous tissue in FGT of premenopausal women. If this is the case, knowledge of BPE measured as an absolute quantity, rather than, as in the BI-RADS system, as a quantity relative to the amount of FGT, would be expected to be a marker of breast cancer risk in pre-menopausal women without there being any requirement to include FGT in the risk assessment. The change in BPE during the menstrual cycle with the least BPE being shown in the second week of the cycle could be in large part due to the "lobular contraction and necrosis" around the perimenstrual period noted by Longacre and Bartow [37] .
The semi-quantitative measures we have made of the immunochemistry stains are likely to be subject to significant intra-and inter-observer variability. The pathology readings were, however, made completely independently of the radiology readings, so it is likely that the true relationships between BPE and the pathology findings are even more definitive than what we observed. Nevertheless, the interpretations we have made must be regarded as tentative until further measurements are made. It would be helpful to also measure breast cell proliferation, but this would only be of use if the MRI could be done immediately before the prophylactic surgery.
The relationships of the pathologic variables to BPE were also seen in post-menopausal patients, but the relationships were much weaker and not statistically significant. BPE is significantly lower after menopause [10] , and our failure to find the planned numbers of post-menopausal patients with moderate/marked BPE decreased our statistical power in this group. Nevertheless, analysis showed that the relationships of the pathologic variables to BPE were considerably weaker in post-menopausal patients. To what extent this may be due to a poorer relationship of the tissues showing BPE to the tissues studied is unknown. Further studies of the biological basis of moderate/marked BPE in post-menopausal women are clearly needed. Prospective studies in which the part of the breast showing high BPE was directly sampled for detailed pathologic analysis are likely to be most informative.
